TY - JOUR
T1 - Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma
T2 - A review of the evidence
AU - Sherman, Mark E.
AU - Drapkin, Ronny I.
AU - Horowitz, Neil S.
AU - Crum, Christopher P.
AU - Friedman, Sue
AU - Kwon, Janice S.
AU - Levine, Douglas A.
AU - Shih, Ie Ming
AU - Shoupe, Donna
AU - Swisher, Elizabeth M.
AU - Walker, Joan
AU - Trabert, Britton
AU - Greene, Mark H.
AU - Samimi, Goli
AU - Temkin, Sarah M.
AU - Minasian, Lori M.
N1 - Funding Information:
This work was supported in part by funding from the National Cancer Institute Intramural Program (B. Trabert and M. Greene), Department of Defense OC130500 (C. Crum), Department of Defense (W81XWH-11-2-0230/OC100517 (I.-M. Shih), Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant (Grant Number SU2C-AACR-DT16-15; E. Swisher). Stand Up to Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, a scientific partner of SU2C.
Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/9
Y1 - 2016/9
N2 - Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research.
AB - Women with clinically detected high-grade serous carcinomas (HGSC) generally present with advanced-stage disease, which portends a poor prognosis, despite extensive surgery and intensive chemotherapy. Historically, HGSCs were presumed to arise from the ovarian surface epithelium (OSE), but the inability to identify early-stage HGSCs and their putative precursors in the ovary dimmed prospects for advancing our knowledge of the pathogenesis of these tumors and translating these findings into effective prevention strategies. Over the last decade, increased BRCA1/2 mutation testing coupled with performance of risk-reducing surgeries has enabled studies that have provided strong evidence that many, but probably not all, HGSCs among BRCA1/2 mutation carriers appear to arise from the fallopian tubes, rather than from the ovaries. This shift in our understanding of the pathogenesis of HGSCs provides an important opportunity to achieve practice changing advances; however, the scarcity of clinically annotated tissues containing early lesions, particularly among women at average risk, poses challenges to progress. Accordingly, we review studies that have kindled our evolving understanding of the pathogenesis of HGSC and present the rationale for developing an epidemiologically annotated national specimen resource to support this research.
UR - http://www.scopus.com/inward/record.url?scp=84987923878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987923878&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-15-0384
DO - 10.1158/1940-6207.CAPR-15-0384
M3 - Review article
C2 - 27221539
AN - SCOPUS:84987923878
SN - 1940-6207
VL - 9
SP - 713
EP - 720
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 9
ER -